The Projected Total Represents Organic Growth Of 10%
• By Akriti Seth
Generate a summary of this article
Listen to this article
After recently rebranding the company, Neuraxpharm has put expansion plans in place that have allowed it to reach over 70% of the European central nervous system market, resulting in projections of organic sales growth of 10% and gross sales of €400m for this year.
Neuraxpharm’s presence in Europe has grown to nine countries • Source: Shutterstock
Neuraxpharm Group is on track to achieve organic net sales growth of 10% in 2019, with expected gross sales of €400m ($436m) this year, the firm has disclosed in a business update.
The central nervous system specialist has broadened its footprint from four to nine European markets in 2019 and aims to...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.